Pentoxifylline as a Potential Adjuvant Therapy for COVID-19: Impeding the Burden of the Cytokine Storm
The outburst of inflammatory response and hypercoagulability are among the factors contributing to increased mortality in severe COVID-19 cases. Pentoxifylline (PTX), a xanthine-derived drug registered for the treatment of vascular claudication, has been reported to display broad-spectrum anti-infla...
Main Authors: | Wiktoria Feret, Magdalena Nalewajska, Łukasz Wojczyński, Wojciech Witkiewicz, Patrycja Kłos, Violetta Dziedziejko, Andrzej Pawlik |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/22/5305 |
Similar Items
-
Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial
by: Rania M. Sarhan, et al.
Published: (2023-04-01) -
INHIBITOR OF SYNTHESIS OF TUMOR NECROSIS FACTOR-Α, PENTOXIFYLLINE, IN COMBINED THERAPY OF THE CHRONIC HEART FAILURE
by: O. P. Dudarenko, et al.
Published: (2016-01-01) -
INHIBITOR OF SYNTHESIS OF TUMOR NECROSIS FACTOR-Α, PENTOXIFYLLINE, IN COMBINED THERAPY OF THE CHRONIC HEART FAILURE
by: O. P. Dudarenko, et al.
Published: (2016-01-01) -
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients
by: Bruce M. Hendry, et al.
Published: (2020-08-01) -
The Roles of Neutrophils in Cytokine Storms
by: Lily Chan, et al.
Published: (2021-11-01)